Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer

Journal of Immunotherapy

Volumn 34, Issue 3, 2011, Pages 289-296

  Huang, Baocheng ^a   Sikorski, Rachel ^a   Sampath, Padma ^a   Thorne, Stephen H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer; histone deacetylase; immunotherapy; metalloproteinase; MICA; MICB; NKG2D

Indexed keywords

METALLOPROTEINASE INHIBITOR; MICA PROTEIN; MICB PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL SURFACE; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; HUMAN; HUMAN CELL; MINNESOTA MULTIPHASIC PERSONALITY INVENTORY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; KILLER CELLS, NATURAL; LIGANDS; METALLOPROTEASES; MICE; MICE, NUDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; SOLUBILITY; TUMOR ESCAPE;

EID: 79953064079     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31820e1b0d     Document Type: Article

References (35)

1. Kirkwood JM. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998;351:1901-1903. (Pubitemid 28297442)
2. Chang AE, Rosenberg SA. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol. 1989;5:385-390. (Pubitemid 20052553)
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
5. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51. (Pubitemid 47026733)
6. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol. 2008;67:93-102.
7. Moingeon P. Cancer vaccines. Vaccine. 2001;19:1305-1326. (Pubitemid 32332715)
8. Wang E, Panelli MC, Monsurro V, et al. A global approach to tumor immunology. Cell Mol Immunol. 2004;1:256-265.
9. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004;23:97-113. (Pubitemid 39446365)
10. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol. 2007;34:524-531. (Pubitemid 350236303)
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915. (Pubitemid 39273730)
12. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J. 2010;16:336-341.
13. Bridgeman JS, Hawkins RE, Hombach AA, et al. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther. 2010;10:77-90.
14. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9: 704-716.
15. Melder RJ, Whiteside TL, Vujanovic NL, et al. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. 1988;48:3461-3469.
16. Sasaki A, Melder RJ, Whiteside TL, et al. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst. 1991;83: 433-437.
17. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687-1696. (Pubitemid 24251113)
18. Verneris MR, Karami M, Baker J, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103:3065-3072. (Pubitemid 38451682)
19. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181-187. (Pubitemid 40287916)
20. Visonneau S, Cesano A, Porter DL, et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res. 2000;6:1744-1754. (Pubitemid 30305067)
21. Tonn T, Becker S, Esser R, et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10:535-544. (Pubitemid 32756192)
22. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-729.
23. Long EO. Tumor cell recognition by natural killer cells. Semin Cancer Biol. 2002;12:57-61. (Pubitemid 34087899)
24. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007;447:482-486. (Pubitemid 46816733)
25. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-738. (Pubitemid 35177960)
26. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 2006;55:1584-1589. (Pubitemid 44327846)
27. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases. Int J Cancer. 2006;118:684-687. (Pubitemid 43076018)
28. Nuckel H, Switala M, Sellmann L, et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia. 2010;24:1152-1159.
29. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321-6329. (Pubitemid 40994418)
30. Skov S, Pedersen MT, Andresen L, et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136-11145. (Pubitemid 41713385)
31. Kirn DH, Wang Y, Le Boeuf F, et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007;4:e353.
32. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311: 1780-1784.
33. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;43:5745.
34. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004;6:96-102. (Pubitemid 38898836)
35. Thorne SH, Liang W, Sampath P, et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol Ther. 2010;18:1698-1705.